Illumina Drops 18% After Earnings as Shorts Continue to Exit

Illumina reported Q3 results on October 29 and the market's verdict was swift: the stock fell 18.3% the following day, closing at $235.99, down 12.4% for the week. That move came against a median gain of roughly 5% among its closest peers, making it one of the sharpest single-session reversals in its recent history.

The irony is that short sellers were not positioned for the drop. Short interest has fallen 17% over the past week alone, and is down nearly 30% over the past month, now at 4.8% of the free float. That is a continuation of the trend flagged before the print: shorts were leaving deliberately, not being squeezed out. The borrow market confirms there was no forced hand involved. Availability runs at 795%, meaning roughly eight shares remain available to lend for every one already borrowed. Cost to borrow is 0.52%, low by any measure and up only modestly from last week's 0.42%. The ORTEX short score has also eased, falling to 41 from 45 a week ago. Positioning, in short, was far more relaxed going into earnings than the reaction warranted.

The analyst community had spent the past month raising targets ahead of the print. Multiple firms lifted estimates through October, with RBC maintaining an Outperform and a $310 target, Guggenheim at $305, Piper Sandler at $305, and Leerink at $300. Evercore ISI, filing the morning after results, kept its Outperform but cut the target to $275 from $290, the first post-earnings target reduction of note. Barclays, already at Underweight, had a $200 target before results. The mean target across the Street now stands at $249.50, which sits above the current price of $235.99 but represents roughly 6% upside, a narrow cushion for a stock that just fell 18% in a day. The debate the Street is working through is familiar: clinical revenue growing at 17% to 20% attracts premium multiples, but customers are actively pressing per-sample pricing, academic demand is soft, and China contributes only around 5% of revenue today versus 10% a few years ago. PE stands at 48x and EV/EBITDA at 31x. At those levels, any signal that the clinical growth rate is decelerating tends to get punished.

Ownership data adds a layer of context. FMR filed a fresh Schedule 13G on October 7 disclosing a 10.7% stake, and BlackRock updated its 13G on October 27 showing 8.9%. Vanguard Capital Management filed on October 30, disclosing 7.58%, up from 5.19% previously. These are passive filings, not activist positions, and there is no Schedule 13D on the register. Director Keith Meister sold over $26 million worth of shares across several transactions in early September at prices around $218 to $219, before the stock's pre-earnings run. There has been no open-market insider buying of consequence. As ever with 13D/G disclosures, stakes are as last disclosed around the 5% threshold and holders can fall below without filing again.

Wikipedia attention spiked sharply around the earnings date, with the retail attention z-score reaching 2.4 as of October 21, well above normal. That kind of attention spike often accompanies large price moves rather than preceding them, and none of the five alt-data datasets covering Illumina has been measured to lead its reported figures. The next earnings event is not until February 5, 2027, leaving 97 days for the dust to settle.

One index story is still live. Illumina was added to the S&P 500 and removed from the S&P MidCap 400 in September, both confirmed and implemented. ORTEX now puts the probability of an additional Nasdaq-100 addition at 44% at the December 2026 Annual Review. The stock needs to close above $284.12 to qualify under the index rules. With the shares at $235.99 after Thursday's fall, that requires a recovery of roughly 20% before the November 30 rank date. The gap has widened considerably in a single session. What to watch now is whether the post-earnings selloff attracts a fresh wave of short interest, reversing the covering trend of the past six weeks, or whether the low borrow cost and loose availability keep the bear case confined to outright equity sellers rather than the lending market.